MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business

Portland, OR, October 28, 2009—MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support the expansion of its cancer molecular diagnostics business...

MolecularMD and Mayo Clinic Enter into Sub-License Agreement for the Detection of Drug Resistant Mutations in Leukemia Patients.

Portland, OR, April 15, 2009—MolecularMD Corp, a developer and provider of cancer-based pharmacogenomic diagnostic tests, announced today that it has granted a sub-license agreement for the detection of ABL kinase mutations in Chronic Myelogenous Leukemia (CML) patients...

Ballast Point Ventures Invests In MolecularMD Corporation

St. Petersburg, Fla, January 15, 2009—Ballast Point Ventures (BPV), a venture capital firm affiliated with Raymond James Financial, Inc. (NYSE-RJF) today announced it has closed a growth equity investment in MolecularMD Corporation....

Exclusive Rights to Patented IP Related to Detection of Resistant BCR-ABL Mutations

PORTLAND, Ore., May 27, 2008—MolecularMD Corp, a developer and provider of cancer-based molecular diagnostics, announced today that it has entered into a license agreement with the Oregon Health & Science University to obtain exclusive commercial...

MolecularMD Joins CML Alliance to Provide Standardized RT-PCR BCR-ABL Patient Monitoring Diagnostics

PORTLAND, Ore., August 6, 2007—MolecularMD, a developer and provider of cancer-based molecular diagnostics, today announced its participation as a preferred provider of Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) patient...

OHSU To Offer Personalized Cancer Diagnostics In New Biotechnology Company

PORTLAND, Ore., May 16, 2007—Oregon Health & Science University has signed an agreement with MolecularMD, a private, molecular diagnostics company founded by scientific investigators including Brian Druker, M.D. The agreement gives OHSU an ownership...

MolecularMD Enters into Agreement with Breakthrough Therapeutics to Support Phase II Clinical Trial

PORTLAND, Ore., August 15, 2006—MolecularMD, a molecular oncodiagnostics company, has recently entered into an agreement with Breakthrough Therapeutics, a private oncology company based in Greenwich, CT, to monitor residual disease levels in patients...

ChemGenex Teams with MolecularMD

MELBOURNE, Australia, and MENLO PARK, California U.S.A., June 26, 2006—ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced an alliance with MolecularMD, Inc., a leading provider of molecular diagnostic services, including drug...

Upcoming Events

No events posted at this time